Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Pediatric glaucoma Indication Strategy Report 2026: TEK, Trials and Deals
24 July 2026
2026 Pediatric glaucoma strategy: epidemiology, TEK biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Fuchs heterochromic iridocyclitis Indication Strategy Report 2026: CMV polymerase, Trials and Deals
24 July 2026
2026 Fuchs heterochromic iridocyclitis strategy: epidemiology, CMV polymerase biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Light chain deposition disease Indication Strategy Report 2026: CD38, Trials and Deals
24 July 2026
2026 Light chain deposition disease strategy: epidemiology, CD38 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Collapsing glomerulopathy Indication Strategy Report 2026: APOL1, Trials and Deals
24 July 2026
2026 Collapsing glomerulopathy strategy: epidemiology, APOL1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Presbyopia Indication Strategy Report 2026: Muscarinic receptor, Trials and Deals
24 July 2026
2026 Presbyopia strategy: epidemiology, Muscarinic receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Monoclonal gammopathy of renal significance Indication Strategy Report 2026: CD38, Trials and Deals
24 July 2026
2026 Monoclonal gammopathy of renal significance strategy: epidemiology, CD38 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Nesidioblastosis Indication Strategy Report 2026: KATP channel, Trials and Deals
24 July 2026
2026 Nesidioblastosis strategy: epidemiology, KATP channel biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Danon disease Indication Strategy Report 2026: LAMP2, Trials and Deals
24 July 2026
2026 Danon disease strategy: epidemiology, LAMP2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Congenital leptin deficiency Indication Strategy Report 2026: LEPR, Trials and Deals
24 July 2026
2026 Congenital leptin deficiency strategy: epidemiology, LEPR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Bardet-Biedl syndrome Indication Strategy Report 2026: MC4R, Trials and Deals
24 July 2026
2026 Bardet-Biedl syndrome strategy: epidemiology, MC4R biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Alström syndrome Indication Strategy Report 2026: ALMS1, Trials and Deals
24 July 2026
2026 Alström syndrome strategy: epidemiology, ALMS1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Familial partial lipodystrophy Indication Strategy Report 2026: LMNA, Trials and Deals
24 July 2026
2026 Familial partial lipodystrophy strategy: epidemiology, LMNA biology, clinical competition, recent deals, unmet need and market attractiveness.